GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axonics Inc (NAS:AXNX) » Definitions » Operating Margin %
中文

Axonics (Axonics) Operating Margin % : 4.19% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Axonics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Axonics's Operating Income for the three months ended in Dec. 2023 was $4.6 Mil. Axonics's Revenue for the three months ended in Dec. 2023 was $109.7 Mil. Therefore, Axonics's Operating Margin % for the quarter that ended in Dec. 2023 was 4.19%.

Good Sign:

Axonics Inc operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Axonics's Operating Margin % or its related term are showing as below:

AXNX' s Operating Margin % Range Over the Past 10 Years
Min: -14198.44   Med: -48.2   Max: -1.29
Current: -1.29


AXNX's Operating Margin % is ranked worse than
53.13% of 815 companies
in the Medical Devices & Instruments industry
Industry Median: 1.28 vs AXNX: -1.29

Axonics's 5-Year Average Operating Margin % Growth Rate was 77.40% per year.

Axonics's Operating Income for the three months ended in Dec. 2023 was $4.6 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.7 Mil.


Axonics Operating Margin % Historical Data

The historical data trend for Axonics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axonics Operating Margin % Chart

Axonics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial -583.21 -48.20 -35.86 -15.49 -1.29

Axonics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.74 -17.83 4.28 -0.74 4.19

Competitive Comparison of Axonics's Operating Margin %

For the Medical Devices subindustry, Axonics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axonics's Operating Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Axonics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Axonics's Operating Margin % falls into.



Axonics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Axonics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-4.712 / 366.379
=-1.29 %

Axonics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=4.596 / 109.735
=4.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Axonics  (NAS:AXNX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Axonics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Axonics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Axonics (Axonics) Business Description

Traded in Other Exchanges
Address
26 Technology Drive, Irvine, CA, USA, 92618
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.
Executives
Karen Noblett officer: Chief Medical Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Kari Leigh Keese officer: Chief Financial Officer 15205 LAFAYETTE WAY, TUSTIN CA 92782
Danny L. Dearen officer: See Remarks 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Ford Alfred J Jr officer: Chief Commercial Officer 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Rinda Sama officer: Chief Operating Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
John Woock officer: Chief Marketing Officer 26 TECHNOLOGY DRIVE, IRVINE CA 92618
Raymond W Cohen director, officer: Chief Executive Officer
Esteban Lopez director 6303 COWBOYS WAY, SUITE 600, FRISCO TX 75034
Jane E Kiernan director 525 W ROSCOE, CHICAGO IL 60657
Robert Mcnamara director C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750
David M Demski director C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Robert E Mcnamara director C/O NORTHSTAR NEUROSCIENCE, INC., 2401 FOURTH AVENUE, SUITE 300, SEATTLE WA 98121
Bakker Juliet Tammenoms director, 10 percent owner LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Partners Andera 10 percent owner 374 RUE SAINT ST HONORE, PARIS I0 75001
Raphael Wisniewski director, 10 percent owner 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920